Overall, TK inhibitor (TKI) therapies have led to deep molecular responses in CML, dramatically improved life expectancy, and more recently, successful treatment-free survival has become a new goal (18). The gene discussed is TKT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.